ID   HOC-7
AC   CVCL_5455
SY   HOC7
DR   cancercelllines; CVCL_5455
DR   Cosmic; 923105
DR   GEO; GSM1291141
DR   Wikidata; Q54890105
RX   PubMed=4016745;
RX   PubMed=23415752;
RX   PubMed=25230021;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Doubling time: 16.4 hours (PubMed=4016745); 26.68 hours (JWGray panel).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=25230021).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Phe (c.824G>T); ClinVar=VCV000376582; Zygosity=Unspecified (PubMed=25230021).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=25230021
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9,11
ST   D16S539: 9
ST   D18S51: 14
ST   D21S11: 30,31.2
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 8,9
ST   D8S1179: 12,14
ST   FGA: 23,25
ST   Penta D: 13
ST   Penta E: 7,12
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C7550; Ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5454 ! HOC-1
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 25
//
RX   PubMed=4016745;
RA   Buick R.N., Pullano R., Trent J.M.;
RT   "Comparative properties of five human ovarian adenocarcinoma cell
RT   lines.";
RL   Cancer Res. 45:3668-3676(1985).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//